KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer. (8th February 2019)

• Record Type: Journal Article
• Authors: Kato, Ken; Shah, Manish A; Enzinger, Peter; Bennouna, Jaafar; Shen, Lin; Adenis, Antoine; Sun, Jong-Mu; Cho, Byoung Chul; Özgüroğlu, Mustafa; Kojima, Takashi; Kostorov, Vladimir; Hierro, Cinta; Zhu, Ying; McLean, Lee Anne; Shah, Sukrut; Doi, Toshihiko
• Is Part Of: Future oncology. Volume 15:Number 10(2019)
• Page Start: 1057
• Page End: 1066
• Publication Date: 2019-02-08
• Subjects: chemotherapy -- esophageal cancer -- esophagogastric junction cancer -- gastrointestinal/esophageal -- immunotherapy -- PD-1 -- PD-L1 -- pembrolizumab -- squamous cell carcinoma of the esophagus; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon-2018-0609
• Languages: English
• ISSNs: 1479-6694

Abstract

Background: Treatment options for patients with advanced esophageal or esophagogastric junction (EGJ) cancer are limited. Current guidelines for first-line treatment of advanced esophageal or EGJ cancer recommend chemotherapy containing a platinum and a fluoropyrimidine agent. Pembrolizumab demonstrated antitumor activity in previously treated patients with advanced esophageal cancer and in patients with gastroesophageal junction cancer.Aim: To describe the design and rationale for the randomized, double-blind, placebo-controlled Phase III KEYNOTE-590 study, which will be conducted to investigate pembrolizumab in combination with chemotherapy as first-line treatment in patients with advanced esophageal or EGJ cancer. Clinical trial registry & ID: ClinicalTrials.gov : NCT03189719.